I have been the lead epidemiologist for IAVI’s Epidemiology for Vaccine Advancement, Capacity and Science research program since 2004, and I joined the UCSF Department of Epidemiology and Biostatistics in 2010. I have worked with teams from 10 clinical research centers across five countries in sub-Saharan Africa to design and guide studies of HIV epidemiology. My interests have been principally cohort development, including multiple studies of HIV incidence in at-risk groups and one of the largest studies of early HIV infection in Africa. The volunteers in these studies represent the diversity of the African HIV epidemic; our teams work in Kenya, Uganda, Rwanda, Zambia and South Africa, with cohorts comprised of risk groups from men who report sex with men, female sex workers and HIV-discordant couples. Our work in these cohorts has included studying the epidemiology of many other pathogens and health-related issues relevant to the communities where we work, ranging from schistosomiasis, to Hepatitis B, to sexually transmitted diseases, and dengue fever, among others. With the acquisition of Aeras TB vaccine clinical programs and assets in 2018, IAVI is positioning itself to be a leader in end-to-end product development for HIV vaccines and TB vaccines, as well as Lassa Fever vaccines, and neutralizing antibodies to prevent and treat HIV infection, snakebite, and antimicrobial resistance. As the Director for Epidemiology at IAVI and associate professor at UCSF, our clinical research studies inform clinical trial design with an eye to answering questions to allow streamlined development of new prevention technologies for HIV and other neglected diseases.